Clinical Trial Update: Study of EGFR-TKI to Asymptomatic Brain Metastases of NSCLC [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study evaluating an epidermal growth factor receptor tyrosine kinase inhibitor in patients with asymptomatic brai…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Non-small Cell Lung Cancer

Drugs mentioned

• EGFR-TKI (EGFR tyrosine kinase inhibitor)

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: Asymptomatic Brain Metastases of Non Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN